JP2021516271A5 - - Google Patents

Info

Publication number
JP2021516271A5
JP2021516271A5 JP2020544672A JP2020544672A JP2021516271A5 JP 2021516271 A5 JP2021516271 A5 JP 2021516271A5 JP 2020544672 A JP2020544672 A JP 2020544672A JP 2020544672 A JP2020544672 A JP 2020544672A JP 2021516271 A5 JP2021516271 A5 JP 2021516271A5
Authority
JP
Japan
Prior art keywords
polymer
alginate
compound
alkyl
formula
Prior art date
Application number
JP2020544672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021516271A (ja
JPWO2019169333A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/020405 external-priority patent/WO2019169333A1/en
Publication of JP2021516271A publication Critical patent/JP2021516271A/ja
Publication of JP2021516271A5 publication Critical patent/JP2021516271A5/ja
Publication of JPWO2019169333A5 publication Critical patent/JPWO2019169333A5/ja
Priority to JP2024010323A priority Critical patent/JP2024052741A/ja
Pending legal-status Critical Current

Links

JP2020544672A 2018-03-02 2019-03-01 抗線維化化合物、デバイス、及びその使用 Pending JP2021516271A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024010323A JP2024052741A (ja) 2018-03-02 2024-01-26 抗線維化化合物、デバイス、及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862637803P 2018-03-02 2018-03-02
US62/637,803 2018-03-02
US201862652883P 2018-04-04 2018-04-04
US62/652,883 2018-04-04
PCT/US2019/020405 WO2019169333A1 (en) 2018-03-02 2019-03-01 Afibrotic compounds, devices, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024010323A Division JP2024052741A (ja) 2018-03-02 2024-01-26 抗線維化化合物、デバイス、及びその使用

Publications (3)

Publication Number Publication Date
JP2021516271A JP2021516271A (ja) 2021-07-01
JP2021516271A5 true JP2021516271A5 (https=) 2022-03-10
JPWO2019169333A5 JPWO2019169333A5 (https=) 2022-03-10

Family

ID=65812415

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020544672A Pending JP2021516271A (ja) 2018-03-02 2019-03-01 抗線維化化合物、デバイス、及びその使用
JP2024010323A Pending JP2024052741A (ja) 2018-03-02 2024-01-26 抗線維化化合物、デバイス、及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024010323A Pending JP2024052741A (ja) 2018-03-02 2024-01-26 抗線維化化合物、デバイス、及びその使用

Country Status (10)

Country Link
US (1) US12605486B2 (https=)
EP (1) EP3759101A1 (https=)
JP (2) JP2021516271A (https=)
KR (1) KR20210004969A (https=)
CN (1) CN112105612A (https=)
AU (2) AU2019226587A1 (https=)
CA (1) CA3092121A1 (https=)
IL (1) IL276753B1 (https=)
TW (1) TW201938592A (https=)
WO (1) WO2019169333A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38389A (es) * 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
US20230003706A1 (en) * 2019-09-27 2023-01-05 Sigilon Therapeutics, Inc. Methods of evaluating small molecule-modified polymers in compositions
CN117940504A (zh) * 2021-06-14 2024-04-26 威廉马什莱斯大学 含有三唑的聚合物及其使用方法
WO2023230524A1 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vi, Llc Compositions of secretory and/or catalytic cells and methods using the same
US20250213470A1 (en) 2022-06-03 2025-07-03 Flagship Pioneering Innovations Vi, Llc Compositions and methods
WO2024006528A1 (en) 2022-07-01 2024-01-04 Sigilon Therapeutics, Inc. Covalently photocrosslinked polysaccharides and methods of use thereof
CN116023525B (zh) * 2023-02-13 2024-03-15 湖北工程学院 一种2-位(1,4-二取代-1,2,3-三唑)修饰的壳聚糖衍生物及其制备方法和应用
TW202435846A (zh) 2023-03-14 2024-09-16 美商希吉隆醫療公司 包含共價交聯多醣及胰島細胞之水膠膠囊
WO2026026917A1 (zh) * 2024-07-31 2026-02-05 北京拓界生物医药科技有限公司 一种修饰的聚合物及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
AU2798599A (en) 1998-02-27 1999-09-15 Bioelastics Research Ltd. Injectable implants for tissue augmentation and restoration
US20090148906A1 (en) 1998-09-29 2009-06-11 Shire Human Genetic Therapies, Inc. A Delaware Corporation Optimized messenger rna
US6361771B1 (en) 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
JP2004532234A (ja) 2001-04-27 2004-10-21 バーテックス ファーマシューティカルズ インコーポレイテッド トリアゾール由来キナーゼインヒビターおよびその使用
WO2004064971A2 (en) 2003-01-23 2004-08-05 Inotech Ag Process for preparing microcapsules having an improved mechanical resistance
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
US20080242694A1 (en) 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
WO2010005533A2 (en) 2008-06-30 2010-01-14 The Johns Hopkins University Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa
AU2010206374B2 (en) 2009-01-23 2013-01-17 Gloriana Therapeutics Sarl Improved cell lines and their use in encapsulated cell biodelivery
JP5725475B2 (ja) 2010-01-21 2015-05-27 公立大学法人名古屋市立大学 ヒドロキサム酸誘導体及びそれを用いたhdac8阻害剤
WO2012112982A2 (en) 2011-02-18 2012-08-23 Massachusetts Institute Of Technology Hydrogel encapsulated cells and anti-inflammatory drugs
WO2012167223A1 (en) 2011-06-02 2012-12-06 Massachusetts Institute Of Technology Modified alginates for cell encapsulation and cell therapy
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9555007B2 (en) 2013-03-14 2017-01-31 Massachusetts Institute Of Technology Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates
US10172791B2 (en) 2013-03-14 2019-01-08 Massachusetts Institute Of Technology Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates
PE20151727A1 (es) 2013-03-14 2015-12-17 Boehringer Ingelheim Int Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
GB201304973D0 (en) 2013-03-19 2013-05-01 Profactor Pharma Ltd Recombinant protein
ITTO20130356A1 (it) 2013-05-03 2014-11-04 Uni Degli Studi Del Piemonte Orientale Ame Inibitori di nicotinamide fosforibosil transferasi, relative composizioni, prodotti ed usi
WO2014182684A2 (en) 2013-05-06 2014-11-13 Cell Machines, Inc. Methods and compositions related to large scale production of proteins
JP2016531149A (ja) 2013-09-11 2016-10-06 ニューロテック ユーエスエー, インコーポレイテッド カプセル化細胞療法カートリッジ
FI3628334T3 (fi) 2014-03-21 2023-09-15 Genzyme Corp Geenihoito verkkokalvon pigmenttirappeuma
CN104072478B (zh) 2014-05-22 2016-06-01 大连理工大学 一类萘环4位含1,2,3-三唑的萘酰亚胺衍生物的合成及其应用
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
JP6723169B2 (ja) 2014-08-01 2020-07-15 マサチューセッツ インスティテュート オブ テクノロジー 抗線維化材料のための修飾されたアルギネートおよび用途
WO2016187225A1 (en) 2015-05-17 2016-11-24 Massachusetts Institute Of Technology Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates
JPWO2017018086A1 (ja) 2015-07-29 2018-02-01 Nissha株式会社 マイクロニードルシート
IL242380A0 (en) 2015-10-29 2016-02-01 Yeda Res & Dev A method of inducing cardiomyocytes proliferation and treating heart diseases
EP3368596A1 (en) 2015-11-01 2018-09-05 Massachusetts Institute Of Technology Materials with improved properties
NZ742800A (en) * 2015-11-01 2019-03-29 Massachusetts Inst Technology Modified alginates for anti-fibrotic materials and applications
WO2017136358A1 (en) 2016-02-01 2017-08-10 Bioverativ Therapeutics Inc. Optimized factor viii genes
AU2017266932B2 (en) 2016-05-18 2023-04-20 Modernatx, Inc. Polynucleotides encoding alpha-galactosidase A for the treatment of Fabry disease
EP3519399A1 (en) 2016-10-03 2019-08-07 Sigilon Therapeutics, Inc. Compounds, devices, and uses thereof
EP3589329B1 (en) 2017-05-11 2022-10-12 Zentrum für Forschungsförderung in der Pädiatrie GmbH Concept for the treatment of monogenetic disorders
WO2019067766A1 (en) 2017-09-27 2019-04-04 Sigilon Therapeutics, Inc. METHODS, COMPOSITIONS AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells

Similar Documents

Publication Publication Date Title
JP2021516271A5 (https=)
RU2012110007A (ru) Имидазохинолины в качестве двойных ингибиторов липидкиназы и mtor
JP2017528444A5 (https=)
JP2021501754A5 (https=)
JP2022506111A5 (https=)
PH12021551116A1 (en) Functionalized heterocycles as antiviral agents
JP2022095872A5 (https=)
JP2018518537A5 (https=)
JP2017526726A5 (https=)
RU2016106152A (ru) Композиция, содержащая гиалуроновую кислоту и мепивакаин
JP2021515083A5 (https=)
JP2018519343A5 (https=)
JP2017524025A5 (https=)
JP2008509928A5 (https=)
JP2013525414A5 (https=)
JP2013520986A5 (https=)
JP2019535723A5 (https=)
US20230313191A1 (en) Rna comprising secretomes and methods of their use
JP2020527382A (ja) N−オキシド及びエクトインモノマー、ポリマー、それらの組成物及び関連方法
MX2021003253A (es) Heterociclos funcionalizados como agentes antivirales.
JP2021516271A (ja) 抗線維化化合物、デバイス、及びその使用
JP2010500962A5 (https=)
JP2011507913A5 (https=)
JP2019500380A5 (https=)
WO2021055425A3 (en) Functionalized heterocycles as antiviral agents